Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
NN3201 in c-Kit expressing solid tumors
NCT06805825Phase 1Recruiting
- Sponsor
- Novelty Nobility
- Start
- Feb 2025
- Primary completion
- Aug 2027
- Modality
- Monoclonal Antibodies, Antibody-Drug Conjugates (ADCs), Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label trial of NN3201 in gastrointestinal stromal tumor (GIST), small cell lung cancer (SCLC), adenoid cystic carcinoma (ACC) and 4 more (4 arms), sponsored by Novelty Nobility. Primary endpoints: Dose-limiting Toxicities at 3 weeks and Adverse Events at 1 year. Started Feb 2025; status: recruiting.
02
Drugs
NN3201
03
Conditions
gastrointestinal stromal tumor (GIST)small cell lung cancer (SCLC)adenoid cystic carcinoma (ACC)Uveal melanoma (UM)Neuroendocrine Neoplasm (NEN)
Beyond the preview
Go deeper on NCT06805825.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06805825.